Peptide and Anti-Aging Specialist Dr. Daniel Benhuri Now Offering Advanced Peptide Therapy, Including Semaglutide, in Beverly Hills and Los Angeles
BEVERLY HILLS, Calif. , June 16, 2025 /PRNewswire/ -- Dr. Daniel Benhuri, a board-certified internal medicine physician and highly rated concierge doctor in Beverly Hills, is now offering a full range of advanced peptide therapies designed to support weight loss, healing, hormone balance, sexual wellness, and cellular rejuvenation. Serving patients throughout Beverly Hills and the greater Los Angeles area, Dr. Benhuri's peptide programs now include widely requested options like Semaglutide, Tirzepatide, Tesamorelin, PT-141, BPC-157, and NAD+.
Peptides are short chains of amino acids that function as biological messengers, helping regulate metabolism, inflammation, recovery, and tissue repair. Dr. Benhuri's therapy protocols are fully customized based on labs, medical history, and patient goals—and are now available through in-office visits or concierge care across Los Angeles.
"Peptide therapy is a powerful tool that allows us to treat the root causes of fatigue, weight gain, inflammation, and low libido," said Dr. Benhuri. "These are evidence-based, well-tolerated therapies that fit perfectly into our concierge wellness model. Our patients want to optimize their lives, and peptides help us deliver exactly that."
Highlights of Dr. Benhuri's peptide therapy offerings include:
Semaglutide and Tirzepatide (GLP-1 agonists): Support sustainable weight loss by regulating appetite and improving insulin sensitivity.
Tesamorelin: Helps reduce visceral fat and promote lean muscle development.
PT-141: Enhances sexual desire and performance in both men and women.
BPC-157: Accelerates healing of soft tissue injuries and provides anti-inflammatory benefits.
NAD+ Therapy: Though not a peptide, NAD+ is a key coenzyme used for energy metabolism, anti-aging, and cognitive enhancement.
Dr. Benhuri's comprehensive programs begin with a detailed consultation and lab review. Based on individual needs, patients receive a personalized treatment plan that may include injectable peptides, nasal sprays, or topical solutions—all sourced from high-quality U.S. compounding pharmacies. Patients also benefit from ongoing clinical monitoring and adjustments as part of his concierge approach.
Known for his expertise in preventive care, weight management, and regenerative medicine, Dr. Benhuri offers these new services as a natural extension of his commitment to helping patients feel better, function better, and age with confidence.
More About Dr. Daniel Benhuri
Dr. Daniel Benhuri is a highly respected internal medicine and primary care physician serving patients in Beverly Hills and the surrounding areas. He offers a vast array of services, including advanced diagnostic imaging, executive physicals, medical weight loss plans, preventive care, and aesthetic treatments. By integrating concierge care and cutting-edge technology, Dr. Benhuri delivers an unmatched level of patient-focused care. His practice is located at 9400 Brighton Way, Suite 210, Beverly Hills, CA 90210. For more information or to schedule an appointment, visit www.danielbenhurimd.com or call (310) 362-1255.
Media ContactDr. Daniel Benhuri(310) 362-1255www.danielbenhurimd.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/peptide-and-anti-aging-specialist-dr-daniel-benhuri-now-offering-advanced-peptide-therapy-including-semaglutide-in-beverly-hills-and-los-angeles-302481967.html
SOURCE Daniel Benhuri M.D.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and Development of Newer Therapies During the Study Period (2020-2034)
The treatment-resistant hypertension (TRH) market is expected to grow in the coming years due to the rising prevalence of uncontrolled hypertension and associated cardiovascular risks. Increasing awareness, improved diagnostic practices, and innovations in combination therapies, as well as device-based interventions, are driving market expansion. LAS VEGAS, July 31, 2025 /PRNewswire/ -- DelveInsight's Treatment Resistant Hypertension Market Insights report includes a comprehensive understanding of current treatment practices, treatment resistant hypertension emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Treatment Resistant Hypertension Market Report Resistant hypertension is managed through a combination of nonpharmacological and pharmacological approaches. Resistant hypertension is initially managed with an ACEi or ARB, a CCB, and a long-acting thiazide diuretic; if uncontrolled, spironolactone is recommended as a fourth-line agent, with β-blockers or α-blockers added if further escalation is needed. The diagnosed prevalence of TRH ranges from 10–14% across the 7MM, suggesting a consistent yet notable burden of the condition. In 2024, there were nearly 13 million diagnosed prevalent cases of TRH across the 7MM, with the United States accounting for the highest number, driven by a major contribution by aging population(40+ age group majorly), heightened awareness of hypertension management as leading pharma companies are focusing on treating resistant patients now, along with ian ncrease diagnosis. In the US in 2024, the highest diagnosed prevalence of treatment-resistant hypertension was observed in adults aged 60 and above, while the lowest was seen in the 18–39 age group, reflecting a clear positive correlation between age and hypertension prevalence. According to DelveInsight's analysis, the market size for treatment resistant hypertension was found to be USD 6.8 billion in the 7MM in 2024, and is projected to grow significantly, driven by the anticipated launch of novel therapies and increased adoption of advanced device-based treatments expected to reshape the treatment landscape. TRYVIO, developed by Idorsia Pharmaceuticals, is the first new class of antihypertensive in nearly 40 years, targeting the endothelin pathway by inhibiting ET-1. Approved by the FDA and EMA in 2024 and by the UK's MHRA in January 2025 for use with other drugs in adults with TRH, it was commercially launched in the US in October 2024. With approval still pending in Japan, the market there remains a significant untapped opportunity for future growth. Followed by TRYVIO's launch in 2024, AstraZeneca's Baxdrostat and Mineralys Therapeutics' Lorundrostat are anticipated to enter the US market by 2026. Out of both the therapies, Lorundrostat's pivotal trial interim data is available; however, Baxdrostat's Phase III data is still awaited. Leading treatment resistant hypertension companies developing emerging therapies, such as AstraZeneca, Mineralys Therapeutics, E-Star BioTech, Ionis Pharmaceuticals, Kardigan, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, Roche, and others, are developing novel treatment resistant hypertension drugs that can be available in the treatment resistant hypertension market in the coming years. The promising treatment resistant hypertension therapies in the pipeline include Baxdrostat (CIN-107), Lorundrostat (MLS-101), MANP, Tonlamarsen (ION904), REGN5381, Zilebesiran (ALN-AGT01), and others. Discover more about the treatment resistant hypertension treatment market @ Treatment Resistant Hypertension Medication Treatment-Resistant Hypertension Market Dynamics The treatment resistant hypertension market dynamics are expected to change in the coming years. Advances in pharmaceuticals and procedures, along with innovations in pharmacogenomics, precision medicine, and digital health platforms, are expanding the landscape of treatment options for TRH by enabling personalized care, enhancing patient engagement and remote management, and necessitating multidisciplinary collaboration among cardiologists, nephrologists, endocrinologists, and other specialists for comprehensive care. Furthermore, potential therapies are being investigated for treatment resistant hypertension, and it is safe to predict that the treatment space will significantly impact the treatment resistant hypertension market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the treatment resistant hypertension market in the 7MM. However, several factors may impede the growth of the treatment resistant hypertension market. Managing TRH often necessitates complex medication regimens and lifestyle modifications, leading to challenges in patient adherence and treatment optimization; however, despite therapeutic advancements, a subset of patients remains resistant to current options, underscoring the need for alternative strategies, even as stringent regulatory and reimbursement hurdles delay new therapy development and adoption, further compounded by the significant economic burden TRH places on healthcare systems, highlighting the urgent need for cost-effective solutions. Furthermore, the treatment resistant hypertension market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the treatment resistant hypertension market growth. Treatment Resistant Hypertension Treatment Market Resistant hypertension is managed through a combination of lifestyle modifications, pharmacological therapy, and, when necessary, interventional procedures. Key lifestyle changes include maintaining a healthy weight through regular exercise and a balanced diet, reducing salt intake, limiting alcohol consumption, and quitting smoking. Pharmacological treatment typically involves a combination of a renin–angiotensin system inhibitor, a long-acting calcium channel blocker, and a diuretic at the highest tolerable doses, preferably as a single-pill formulation. Spironolactone is currently the preferred fourth-line agent, while alternatives include alpha-blockers, beta-blockers, centrally acting sympatholytics, and vasodilators. For patients whose blood pressure remains uncontrolled despite these strategies, options such as renal denervation and emerging drug therapies should be considered. Lifestyle interventions are particularly important, with a recent meta-analysis identifying them as the most effective non-pharmacologic approach, achieving a reduction in office systolic blood pressure by approximately 7.26 mmHg. Dietary patterns such as the DASH and Mediterranean diets, characterized by high intake of fruits, vegetables, whole grains, and low-fat dairy, and low levels of saturated fats and sugars, have shown proven benefit. Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, offers a promising alternative by blocking aldosterone activity even in its absence. While spironolactone remains the standard add-on therapy, its anti-androgenic effects may limit its use, especially in men or those with hyperkalemia. TRYVIO (aprocitentan) marks a significant advancement as the first antihypertensive from a new drug class in over three decades, targeting the endothelin pathway. Approved by the FDA in early 2024, TRYVIO is a convenient once-daily oral therapy that simplifies prescribing and adherence. The removal of the REMS requirement by the FDA signals increased confidence in its safety. Though it's now available for patients at high cardiovascular risk, fluid retention, reported in 18% of patients at higher doses, which may affect its adoption compared to existing options. While Idorsia has not yet revealed a global commercialization partner, the positive Phase III outcomes indicate strong market potential for TRYVIO. To know more about FDA-approved drugs for treatment resistant hypertension, visit @ Treatment Resistant Hypertension Treatment Treatment Resistant Hypertension Pipeline Therapies and Key Companies Several TRH drugs with different mechanisms of action that are in development are aldosterone synthase inhibitors (baxdrostat, lorundrostat), Guanylyl Cyclase A (GC-A) receptor activators (MANP), Natriuretic Peptide Receptor 1 (NPR1) agonists (REGN5381), angiotensinogen expression inhibitors (zilebesiran), and targeting angiotensinogen (tonlamarsen). The success of these candidates could diversify the treatment landscape and intensify competition. Baxdrostat is an oral, small-molecule drug that selectively inhibits aldosterone synthase, the enzyme responsible for producing aldosterone in the adrenal glands. Baxdrostat emerges as a strong contender in the resistant hypertension pipeline, with AstraZeneca positioning it as a potential multi-blockbuster asset. As an oral aldosterone synthase inhibitor, it targets patients with uncontrolled or resistant hypertension. The Phase II results have shown significant reductions in SBP, outperforming TRYVIO, with a favorable safety profile. First, mention the drug's current phase. The Phase III results, expected in the second half of 2025, will be key in validating its commercial and clinical potential. Lorundrostat, another Phase III investigational oral therapy. It is gaining attention as a high-potential entrant in the antihypertensive market. Developed by Mineralys Therapeutics, the drug is a highly selective oral aldosterone synthase inhibitor, and early data positions it as a potential best-in-class option for patients with resistant or uncontrolled hypertension. Positive outcomes from both the Phase II Advance-HTN and Phase III Launch-HTN trials validate its clinical promise, with efficacy surpassing that of TRYVIO in terms of blood pressure reduction. What further strengthens Lorundrostat's profile is its superior selectivity and greater reduction in plasma aldosterone concentration compared to baxdrostat. With approximately four times higher selectivity, the drug may offer a more targeted approach to managing cardiorenal metabolic conditions, a segment with significant unmet clinical needs. The anticipated launch of these emerging therapies are poised to transform the treatment resistant hypertension market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the treatment resistant hypertension market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. Discover more about treatment resistant hypertension drugs in development @ Treatment Resistant Hypertension Clinical Trials Recent Developments in the Treatment Resistant Hypertension Market In May 2025, Q1 presentation, Alnylam Pharmaceuticals and Roche announced plans to release the topline results from the KARDIA-3 study and to initiate a Phase III cardiovascular outcomes trial of zilebesiran in the second half of 2025. In the Q1 2025 presentation, Regeneron Pharmaceuticals announced the initiation of a Phase II clinical trial evaluating REGN5381 for the treatment of uncontrolled hypertension. In March 2025, Idorsia Pharmaceuticals announced that the US FDA had fully released TRYVIO from its REMS requirement. Idorsia has also released from the PMR to conduct a worldwide descriptive study that collects prospective and retrospective data in women exposed to TRYVIO during pregnancy and/or lactation, as these data are no longer needed. In February 2025, Idorsia Pharmaceuticals announced that the exclusivity agreement signed in November 2024 with an undisclosed party for the global rights to aprocitentan had concluded without the party signing the deal as foreseen in the nonbinding term sheet. Treatment Resistant Hypertension Overview Resistant hypertension is characterized by blood pressure that remains elevated at or above 130 mmHg systolic and 80 mmHg diastolic, despite the use of three or four different classes of antihypertensive medications, including a thiazide diuretic, all at their highest tolerated doses. It can also refer to cases where blood pressure is controlled, but only with the use of four or more antihypertensive agents. This definition encompasses both resistant and refractory hypertension in patients whose blood pressure remains uncontrolled despite being on an adequate regimen that includes a diuretic. Individuals who require more than three medications to control their blood pressure may also benefit from referral to a hypertension specialist. The assessment of resistant hypertension begins with confirming the accuracy of blood pressure readings, as mistakes such as using an improperly sized cuff or incorrect arm positioning can lead to misleadingly high values. It is also important to rule out the white coat effect by using validated out-of-office monitoring methods, such as ambulatory or home blood pressure monitoring under clinical guidelines. Automated office blood pressure (AOBP) measurement, which involves repeated readings taken every 1–2 minutes with the patient alone in a quiet room using a specialized oscillometric device, is a useful technique to reduce this effect. Treatment Resistant Hypertension Epidemiology Segmentation The treatment resistant hypertension epidemiology section provides insights into the historical and current treatment resistant hypertension patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The treatment resistant hypertension market report offers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Diagnosed Prevalent Cases of Treatment Resistant Hypertension Gender-Specific Diagnosed Prevalent Cases of Treatment Resistant Hypertension Age-Specific Diagnosed Prevalent Cases of Treatment Resistant Hypertension Treatment Resistant Hypertension Market Report Metrics Details Study Period 2020–2034 Coverage 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan]. Treatment Resistant Hypertension Market CAGR 5 % Treatment Resistant Hypertension Market Size in 2024 USD 6.8 Billion Key Treatment Resistant Hypertension Companies AstraZeneca, Mineralys Therapeutics, E-Star BioTech, Ionis Pharmaceuticals, Kardigan, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, Roche, Idorsia Pharmaceuticals, and others Key Treatment Resistant Hypertension Therapies Baxdrostat (CIN-107), Lorundrostat (MLS-101), MANP, Tonlamarsen (ION904), REGN5381, Zilebesiran (ALN-AGT01), TRYVIO/JERAYGO, and others Scope of the Treatment Resistant Hypertension Market Report Therapeutic Assessment: Treatment Resistant Hypertension current marketed and emerging therapies Treatment Resistant Hypertension Market Dynamics: Key Market Forecast Assumptions of Emerging Treatment Resistant Hypertension Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Treatment Resistant Hypertension Market Access and Reimbursement Download the report to understand the treatment resistant hypertension market trends @ Treatment Resistant Hypertension Market Report Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 TRH Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Therapies of TRH in 2024 6.2 Market Share (%) Distribution by Therapies of TRH in 2034 7 Disease Background and Overview 7.1 Introduction 7.2 Symptoms 7.3 Risk Factors 7.4 Pathophysiology of TRH 7.5 Diagnosis 7.6 Treatment 7.7 Diagnostic Guidelines and Recommendations TRH 7.7.1 European Society of Cardiology (ESC) Recommendations for Hypertension 7.8 Treatment Guidelines and Recommendations for TRH 7.8.1 European Society of Cardiology (ESC) Recommendations for Resistant Hypertension (2024) 7.8.2 European Society of Hypertension (ESH) Recommendations of Lifestyle Interventions in Management of Hypertension (2023) 7.8.3 American Heart Association (AHA) Recommendations for Resistant Hypertension (2020) 7.8.4 The Japenese Socitey of Hypertension Guidelines for the Management of Hypertension (JSH 2019) 8 Epidemiology and Patient Population 8.1 Key Findings 8.2 Assumptions and Rationale 8.3 Total Diagnosed Prevalent Cases of TRH in the 7MM 8.4 The United States 8.4.1 Total Diagnosed Prevalent Cases of TRH in the United States 8.4.2 Gender-specific Diagnosed Prevalent Cases of TRH in the United States 8.4.3 Age-specific Diagnosed Prevalent Cases of TRH in the United States 8.5 EU4 and the UK 8.6 Japan 9 Patient Journey 10 Marketed Drugs 10.1 Key Cross 10.2 TRYVIO/JERAYGO (aprocitentan): Idorsia Pharmaceutical 10.2.1 Product Description 10.2.2 Regulatory Milestones 10.2.3 Other Developmental Activities 10.2.4 Safety and Efficacy 10.2.5 Analyst View 11 Emerging Drugs 11.1 Key Cross Competition 11.2 Baxdrostat (CIN-107): AstraZeneca 11.2.1 Product Description 11.2.2 Other Development Activity 11.2.3 Clinical Development 11.2.4 Safety and Efficacy 11.2.5 Analyst View 11.3 Lorundrostat (MLS-101): Mineralys Therapeutics 11.4 MANP: E-Star BioTech 11.5 Tonlamarsen (ION904): Ionis Pharmaceuticals and Kardigan 11.6 REGN5381: Regeneron Pharmaceuticals 11.7 Zilebesiran (ALN-AGT01): Alnylam Pharmaceuticals and Roche 12 TRH: Seven Major Market Analysis 12.1 Key Findings 12.2 Market Outlook 12.3 Key Market Forecast Assumptions 12.4 Conjoint Analysis 12.5 Total Market Size of TRH in the 7MM 12.6 Market Size of TRH by Therapies in 7MM 12.7 The United States Market Size 12.8 EU4 and the UK Market Size 12.9 Japan 13 Unmet Needs 14 SWOT Analysis 15 KOL Views 16 Market Access and Reimbursement 16.1 United States 16.2 EU4 and the UK 16.3 Japan 16.4 Market Access and Reimbursement of TRH 17 Bibliography 18 Report Methodology Related Reports Treatment Resistant Hypertension EpidemiologyTreatment Resistant Hypertension Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the TRH epidemiology trends. Hypertension MarketHypertension Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hypertension companies, including Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc., Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical, among others. Hypertension PipelineHypertension Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hypertension companies, including Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc., Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical, among others. Tyrosine Kinase Inhibitors MarketTyrosine Kinase Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key TKIs companies, including AstraZeneca, Novartis, AbbVie, Eisai, Pfizer, F. Hoffmann-La Roche, Bristol-Myers Squibb, Bayer, Boehringer Ingelheim, Johnson & Johnson, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ + Logo: View original content: SOURCE DelveInsight Business Research, LLP Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
6 hours ago
- Yahoo
Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC
HONG KONG, July 30, 2025 /PRNewswire/ -- Akeso, Inc. ( ("Akeso" or the "Company") announced that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMONi-8A) of ivonescimab (PD-1/VEGF bispecific antibody) in combination with docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed following PD-1/L1 inhibitors and platinum-based chemotherapy. Ivonescimab is the only bispecific immunotherapy antibody currently undergoing Phase III registration trials for IO-resistant lung cancer. In recent years, immunotherapy has achieved significant progress in the treatment of NSCLC. PD-1/L1 inhibitors, whether used as monotherapy or in combination with platinum-based chemotherapy, have become the standard first-line treatment for advanced NSCLC in patients without driver mutations. However, despite these advances, 60%-70% of patients experience disease progression within the first year of treatment. Currently, there are no approved standard treatment options for IO-resistant NSCLC. Docetaxel is recommended in both China's and international treatment guidelines for immunotherapy-resistant (IO-resistant) NSCLC. However, docetaxel's monotherapy efficacy in the IO-resistant NSCLC patients remains limited. Several Phase III clinical trials investigating IO-resistant lung cancer, including immunotherapy combination therapies studies and ADC therapy studies, have failed to demonstrate positive results. Mechanistic studies suggest that PD-1 therapy can restore the immune system's anti-tumor activity, while anti-VEGF therapy alleviates VEGF-mediated immune suppression and promotes T-cell infiltration. When combined, these two therapies may produce synergistic effects. Ivonescimab simultaneously targets both PD-1 and VEGF pathways, reversing the immune-suppressive tumor microenvironment and reactivating anti-tumor immune responses. These synergistic mechanisms provide a scientific rationale for using ivonescimab to treat IO-resistant tumors. Furthermore, the positive efficacy and safety data demonstrated in a Phase II study in this indication underscore the significant therapeutic potential of ivonescimab in this difficult to treat patient population. The ivonescimab regimen has demonstrated remarkable efficacy and excellent safety across multiple tumor types. The ongoing AK112-305/HARMONi-8A Phase III study targeting IO-resistant NSCLC is expected to offer a novel and highly effective treatment option for patients with IO-resistant NSCLC, in line Akesos ' 'Immuno-2.0' strategy. As the world's leading PD-1/VEGF bispecific antibody, ivonescimab has achieved extensive population coverage for core indications in NSCLC and is positioned across multiple lines of treatment, with the potential to reshape the overall treatment landscape for advanced NSCLC. Forward-Looking Statement of Akeso, announcement by Akeso, Inc. ( "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. About AkesoAkeso (HKEX: is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit and follow us on Linkedin. View original content: SOURCE Akeso, Inc.
Yahoo
7 hours ago
- Yahoo
123Invent Inventor Develops Salt Bath to Detoxify and Reduce Aches (HWT-3068)
PITTSBURGH, July 31, 2025 /PRNewswire/ -- "I wanted to create an easy way for individuals with ADHD and autism to reduce pain and enjoy a detoxifying soak," said an inventor, from Aurora, Colo., "so I invented the TREETOX. My conveniently packaged design eliminates the need to find and combine all the individual ingredients." The invention provides an effective way to help detoxify. It also reduces aches and pains. As a result, it offers an alternative to traditional bath salts and detoxifying products. The invention features a simple and effective design that is easy to use so it is ideal for individuals with ADHD and autism. TREETOX is currently available for licensing or sale to manufacturers or marketers. For more information, visit Or contact Theresa Ayala at 720-771-1638 or email info@ View original content to download multimedia: SOURCE InventHelp Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
